C-MER Medical (03309) disclosed that on 20 February 2026, 0.13 million ordinary shares were repurchased on the market, representing approximately 0.0107% of the then-existing issued shares. The highest repurchase price reached HKD 1.53 per share, while the lowest was HKD 1.49.

Before the transaction, the company had 1.21 billion issued shares (excluding treasury shares) and 20.29 million treasury shares, totaling 1.23 billion shares. Following the repurchase, the issued shares (excluding treasury shares) decreased to 1.21 billion, with treasury shares increasing to 20.42 million. The total shares remained at 1.23 billion.

The aggregate price of the 0.13 million shares repurchased on 20 February 2026 was HKD 196,140. According to the repurchase mandate approved on 19 May 2025, the maximum authorized repurchase limit reached 125.56 million shares. As indicated, a moratorium period for any new share issuance or sale of treasury shares will continue up to 22 March 2026.